Inpatient costs of congenital heart surgery in China: Results from the National Centre for Cardiovascular Diseases

LATEST ARTICLES
SEARCH INDEX
SUGGEST ARTICLE
THE OSI COLLECTIONS
AUDIOGRAM SERIES
ABOUT THE OSI
2020 SUMMARY
2021 SUMMARY

OSI STATISTICS

Open access articles:
1592
Annotations added:
3
Countries represented:
117
No. of contributors:
15
Bookmarks made:
26

Inpatient costs of congenital heart surgery in China: Results from the National Centre for Cardiovascular Diseases


JournalThe Lancet Regional Health – Western Pacific
Article typeJournal research article – Clinical research
Publication date – Nov – 2022
Authors – Qiyu He (何奇彧), Zheng Dou (窦铮), Zhanhao Su (苏展豪), Huayan Shen (沈华宴), Tsz-Ngai Mok (莫子艺), Casper J. P. Zhang,e Jian Huang, Wai-Kit Ming, Shoujun Li (李守军)
Keywordscongenital heart disease, economic burden, health policy, Inpatient costs, surgery
Open access – Yes
SpecialityCardiothoracic surgery, Paediatric surgery
World region Eastern Asia
Country: China
Language – English
Submitted to the One Surgery Index on December 3, 2022 at 2:06 am
Abstract:

Background
Economic data on congenital heart disease (CHD) in China are scarce. Therefore, this study aimed to explore the inpatient costs of congenital heart surgery and related healthcare policies from a hospital perspective.

Method
We used data from the Chinese Database for Congenital Heart Surgery (CDCHS) to prospectively analyse the inpatient costs of congenital heart surgery from May 2018 to December 2020. The total expenditure was divided into 11 columns (medications, imaging, consumable items, surgery, medical cares, laboratory tests, therapy, examinations, medical services, accommodations, and others), and explored according to the Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STAT) category, year, different age group, and CHD complexity. Authority economic data (index for gross domestic product [GDP], GDP per capita, per capita disposable income and average annual exchange rate of 2020 Chinese Yuan against US dollar) were accessed via the National Bureau of Statistics of China to better describe the burden. In addition, potential factors contributing to the costs were also investigated by using generalised linear model.

Findings
All values are presented in 2020 Chinese Yuan (¥). A total of 6568 hospitalisations were enrolled. The median of overall total expenditure was ¥64,900 (≈9409 US Dollar [USD], interquartile range [IQR]: ¥35,819), with the lowest in STAT 1 (¥57,014 ≈ 8266 USD, [IQR]: ¥16,774) and the highest in STAT 5 (¥194,862 ≈ 28,251 USD, [IQR]: ¥130,010). The median costs during the 2018 to 2020 period were ¥62,014 (≈8991 USD, [IQR]: ¥32,628), ¥64,846 (≈9401 USD, [IQR]: ¥34,469) and ¥67,867 (≈9839 USD, [IQR]: ¥41,496). Regarding to age, the median costs were highest in the ≤1 month group (¥144,380 ≈ 20,932 USD, [IQR]: ¥92,584). Age, STAT category, emergency, genetic syndrome, delay sternal closure, mechanical ventilation time, and complications were significantly contributed to the inpatient costs.

Interpretation
For the first time, the inpatient costs of congenital heart surgery in China are delineated in detail. According to the results, CHD treatment has achieved significant progress in China, but it still causes substantial economic burden to both families and society. In addition, ascending trend of the inpatient costs was observed during the period of 2018–2020, and the neonatal was revealed to be the most challenging group.

Funding
This study was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS,2020-I2M-C&T-A-009), Capital Health Research and Development of Special Fund (2022-1-4032), and The City University of Hong Kong New Research Initiatives/Infrastructure Support from Central (APRC, 9610589).

OSI Number – 21833

Public annotations on this article:
No public annotations yet